GOTHENBURG, Sweden, April 24, 2025 /PRNewswire/ --

First quarter

• Sales of SEK 842 (841) million, an increase of 1% in local currencies and 0% in SEK. The growth in local currencies excluding discontinued business was 3%. 
• Sales per region, in local currencies was +8% in EMEA, +14% excluding discontinued business, +9% in Americas and -15% in APAC. 
• Sales per product groups, in local currencies excluding discontinued business was +6% in Consumables, -5% in Technologies and +4% in Genetics. 
• Sales per product groups, in local currencies was +3% in Consumables, -6% in Technologies and +1% in Genetics. 
• Gross margin increased to 57.4% (57.1).
• Earnings before depreciation and amortisation (EBITDA) decreased to SEK 257 (272) million, giving an EBITDA margin of 30.6% (32.4), affected by foreign exchange impact of SEK -13 (1) million. 
• Operating cash flow amounted to SEK 69 million (198). 
• Net income was SEK 100 (115) million, resulting in earnings per share of SEK 0.74 (0.85).

Gothenburg, April 24, 2025

VITROLIFE AB (publ)

Bronwyn Brophy O´Connor, CEO

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 24-04-2025 08:00 CET.

For more information, please contact: 

Helena Wennerström, acting CFO, phone: +4670 822 80 86

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/vitrolife-ab--publ-/r/interim-report-q1--2025--strong-performance-in-emea,c4139505

The following files are available for download:

View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-publ-interim-report-q1-2025-strong-performance-in-emea-302436973.html

SOURCE Vitrolife AB (publ)